NCT05176080 2024-12-17
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Henan Cancer Hospital
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT06332950 2024-03-27
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT04044378 2020-05-19
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Peking University People's Hospital
Phase 1/2 Withdrawn